Rize Medical Cannabis and Life Sciences UCITS ETF (FLWR)

R I D I N G T H E C O A T T A I L S O F A B U D D I N G I N D U S T R Y

An ETF that rises above the tide of conventionalism as your investments should

1

Investment Case Why FLWR?

Medical cannabis has the potential to help millions of people globally. The stigma is coming down, and the cannabis plant is metamorphosing from a vice steeped in political, legal and cultural controversy to a medicine hailed for its remarkable therapeutic applications. Today, the movement is backed by the tailwinds of favourable legislation, social acceptance, medical recognition and pharmaceutical applications. Cannabis-derived pharmaceutical drugs are now available to treat symptoms associated with multiple sclerosis, certain types of cancer and rare forms of childhood epilepsy, including Lennox- Gastaut syndrome and Dravet syndrome. Our purpose-built investment strategy and ETF – the first truly global Medical Cannabis ETF in Europe – provides investors with access to those companies that are positively exposed to this revolution in cannabis-derived medicine.

As the medical cannabis movement gathers steam, catalysed by breakthroughs in our understanding of cannabinoids and the corresponding trend towards liberalisation and legalisation, getting on the front foot of this megatrend has its perks for those who can spot the investment opportunity today.

• Favourable Growth Prospects FLWR is Europe’s first global medical cannabis ETF, and provides investors with exposure to the global revolution in cannabis-derived medication and wellness products.

• Powered by New Frontier Data® FLWR is purpose-built in collaboration with New Frontier Data, an independent cannabis research and tech-driven analytics firm based in Washington, D.C., and leverages their unique insights and proprietary classification system of companies that have demonstrable exposure to the medical cannabis and life sciences sector.

• Unconstrained Approach FLWR’s composition transcends classic sector, size and geographic classifications by tracking an emerging theme.

• �ETF�Efficiency In a single trade, FLWR delivers access to dozens of companies that are favourably positioned to ride the tailwinds of the medical cannabis and life sciences theme.

Key Risks: Please note that the value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested. If your investment currency is different to USD, then the return you will get from your investment may increase or decrease as a result of currency fluctuations between USD and your investment currency.

2

W H O S H O U L D C O N S I D E R T H I S E T F ?

3

Investors who are...

• Seeking capital appreciation through investment in companies that are strategically positioned to benefit from the global revolution in cannabis-derived medicine and wellness solutions.

• Interested in a diverse portfolio of stocks with a small to mid-cap bias, and minimal overlap to major benchmarks such as the S&P 500 or the Nasdaq.

• Biotechnology/pharma executives, medical researchers, cannabis business owners or general market enthusiasts.

Key Risks: Please note that the value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested. If your investment currency is different to USD, then the return you will get from your investment may increase or decrease as a result of currency fluctuations between USD and your investment currency.

4

Medical cannabis is a global phenomenon

Source: New Frontier Data 2020

Legal medical use cannabis

5

$8.3

$9.8

$12.4

$14.5

$16.5

$20.1

$4.5

U.S. legal cannabis market projections

Source: New Frontier Data 2020

2017

Billi

ons

2018

2019

2020

2021

2022

2023

2024

2025

$10

$5

$0

$15

$20

$25

$3.2

$10.6

$3.2

$11.2

$10.4$9.5

$8.5

$7.3

$6.2

$5.4$11.8

$7.0

$5.4

$8.3$9.2 $10.0

$11.1

2017 - 2025 CAGR 13.7%$18.4

$21.6

$23.0

Adult use Medical

6

Legalisation timeline in the United States

1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018

1996CA

2010NJ & AZ

2013NH & IL

2014MN, NY & MD

2007NM

2000HI, NV & CO

1998OR, AK & WA

2004VT & MT

2008MI

2011DE

2014AK & OR

2018VT

2006RI

2009DC

2012CT & MA

1999ME

2016PA, OH, AR, FL & ND

2015LA

2012CO & WA

2016CA, NV, ME & MA

2015DC

Source: New Frontier Data 2020Medical Adult use

7

Source: New Frontier Data 2020

Top 7 potential European cannabis markets for legal medical use

$U.S

.D. B

illio

ns

$4

$2

$0

$6

$8

$10

$12

Range of uncertiainty due to pricing variation within region.

$9.5

Fran

ce

$10.5

Italy

$9.7

Ger

man

y

Unite

d Ki

ngdo

m

$4.6

Spai

n

$4.3Po

land

$2.5 $1.8

Czec

h Re

pulic

$42.9Billion

Potential combined market value

Largest total addressable market value ($USD in billions)

8

9

10

Company Product Technology Indication Location

ArenaPharmaceuticals

APD371 Highly selective CB2 full agonist

Crohn’s disease and inflammatory bowel diseaes (IBD)

San Diego, CA

CaraTherapeutics

CR701 CB1/CB2 agonist Neuropathic pain Shelton, CT

VitalityBiopharma

VB100VB210

Cannaboid glycoside prodrugs

Symptoms of IBD, MS, fibromy-algia and neuropathic pain

Los Angeles, CA

ZynerbaPharmaceuticals

ZYN001 /ZYN002

THC pro-drug/CBD gel Refractory epilepsy, Fragile X syndrome/neuropathic pain

Devon, PA

InsysTherapeutics

Cannabidiol Cannabidiol Severe pediatric epilepsies

Chandler, AZ

AbideTherapeutics

ABX-1431 MGL inhibitor Dyspepsia San Diego, CA

University ofCalifornia, Irvine

URB937 Peripheral FAAH inhibitor

Inflammatory and acute pain Irvine, CA

Syqe/TEVA Vaporizer Herbal cannabis Chronic neuropathic pain Tel Aviv, IS

GWPharmaceuticals

Nabiximols /Sativex

Herbal cannabis ethanolic extract

Spasticity associated to MS, chronic pain

Cambridge, UK

GWPharmaceuticals

Epidiolex Highly purified form of cannabidiol (CBD)

Seizures associated with Dravet and LGS

Cambridge, UK

Source: New Frontier Data 2020

Top conditions for which medical cannabis is recommended in the U.S.

Sample companies developing cannabis-derived pharmaceuticals

• HIV or AIDS

• Chronic Pain

• Cancer

• Crohn’s Disease

• Multiple Sclerosis

• Nausea

• Glaucoma

• Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease)

• Seizures

• PTSD

• Cachexia/Wasting syndrome

• Hepatitis C

• Intractable Spasticity

• Alzheimer’s Disease

• Epilepsy

• Parkinson’s Disease

11

U.S. total CBD sales by channel (in USD millions)

Source: New Frontier Data 2020

2014

2015

2016

2017

2018

2019

2020

2021

2022

Hem

p-de

rived

Mar

ijuan

a-de

rived

Phar

mac

eutic

al

$1000

$500

$0

$1500

$2000

Total U.S. market$108 $178 $260 $367 $534 $845 $1197 $1614 $1918

$59$59

$98

$80

$131

$129

$177

$190

$30$177

$190

$180

$313

$352

$340

$407

$450

$550

$516

$548

$625

$647

$646

Epidiolex

12

A Unique Approach to Thematic Investing

We have created an ETF capability that leverages the best of thematic research and rules-based implementation to deliver solutions that are purpose-built for the thematic investing community. We achieve this by working with leading specialists in each of our themes, in addition to your typical index provider. In this way, we are able to purpose-build all of our investment strategies, which are then codified into indices. We believe that working with experts is the best way to successfully capture the secular, technical and behavioural drivers of a theme, and adopt a targeted approach in accessing the companies that are best placed to benefit.

We believe out-of-the- box research has the power to unlock ground breaking insights.

13

New Frontier Data®

About The Partners

Rize ETF has partnered with New Frontier Data (“NFD”) to power up the Rize Medical Cannabis and Life Sciences UCITS ETF. NFD is an independent, technology-driven analytics firm specialising in the global cannabis industry. Its mission is to elevate the discussion around legal cannabis globally. It offers vetted data, actionable business intelligence, and risk management solutions for investors, operators, researchers and policymakers alike. NFD’s reports and data have been cited in over 80 countries. The company is headquartered in Washington, D.C. with additional offices in Denver, CO, and London, UK.

Foxberry®

Rize ETF has engaged Foxberry Limited (“Foxberry”) to administer the index replicable by the Rize Medical Cannabis and Life Sciences UCITS ETF. Foxberry are an independent index administrator with state-of-the-art index management, structuring, analysis and technological capabilities typically only found within top-tier investment banks. Foxberry is authorised and regulated by the FCA and registered under the EU benchmark regulation.

14

The Foxberry Medical Cannabis & Life Sciences Index provides exposure to companies in the global medical cannabis and cannabis-related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol sectors. The index excludes companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol for the recreational consumer market. The index follows a liquidity-based weighting scheme where companies with higher liquidity achieve a bigger weight in the index.

About The Index

S T A T E O F T H E A R T I N D E X M A N A G E M E N T

15

Portfolio Characteristics

Source: Bloomberg as of close 31 December 2019

Biotechnology/Pharma Agriculture Tech & Supplies Hemp & CBD Big Pharma

Small cap Mid cap Large cap

United States United Kingdom Canada Israel

Switzerland Ausralia Colombia Hong Kong

New Frontier Data Classification

Market Cap Breakdown

CountryBreakdown

0.42%

0.93%

3.08%

3.41%

4.64%

0.48%

14.80%

72.24%

10.20%

45.13%

44.67%

10.20%15.28%

15.76%

58.76%

0.42%

0.93%

3.08%

3.41%

4.64%

0.48%

14.80%

72.24%

10.20%

45.13%

44.67%

10.20%15.28%

15.76%

58.76%

0.42%

0.93%

3.08%

3.41%

4.64%

0.48%

14.80%

72.24%

10.20%

45.13%

44.67%

10.20%15.28%

15.76%

58.76%

16

Performance ChartRebased to 100

180

200

160

140

120

100

80

60

40

Dec 2017 Mar 2018 Mar 2019Jun 2018 Jun 2019Sept 2018 Sept 2019Dec 2018 Dec 2019

Foxberry Medical Cannabis & Life Sciences Index North American Marijuana Index

Source: Bloomberg 2020.Past performance is not a guide to future performance. The performance shown relates to the Foxberry Medical Cannabis & Life Sciences Index as compared against the performance of the North American Marijuana Index which is comprised of a basket of North American publicly listed companies with significant business activities in the marijuana industry. Foxberry Medical Cannabis & Life Sciences Index: The calculation of this index began on 24 January 2020 and therefore it is not possible to show actual performance for any complete 12 month periods. Accordingly, the performance shown is simulated and based on back-tested data and relates to the period between 31 December 2017 and 31 December 2019. Simulated past performance does not represent actual performance and should not be used as a guide to actual or future performance. North American Marijuana Index: The calculation of this index began on 02 March 2017 and therefore it is not possible to show actual performance for any complete 12 month periods prior to 2018. Accordingly, the performance shown is actual past performance relating to the period between 31 December 2017 and 31 December 2019. Both indices: All performance and volatility data is in USD, unless otherwise stated. Volatility has been calculated as the two-year annualised standard deviation of the daily returns. The performance data shown does not reflect the transaction costs and management fees incurred or charged by financial products such as FLWR. Please note that the value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested. If your investment currency is different to USD, then the return you will get from your investment may increase or decrease as a result of currency fluctuations between USD and your investment currency.

17

Performance Table & Risk Metrics

Indices

Foxberry Medical Cannabis & Life Sciences Index

3 M

-8.7%

-17.5% -31.5% -48.4%

-0.8% -23.1% 32.7%

44.7%

1 Year 2 Year

North American Marijuana Index

Performance in USD

Volatility

Source: Bloomberg 2020.Past performance is not a guide to future performance. The performance shown relates to the Foxberry Medical Cannabis & Life Sciences Index as compared against the performance of the North American Marijuana Index which is comprised of a basket of North American publicly listed companies with significant business activities in the marijuana industry. Foxberry Medical Cannabis & Life Sciences Index: The calculation of this index began on 24 January 2020 and therefore it is not possible to show actual performance for any complete 12 month periods. Accordingly, the performance shown is simulated and based on back-tested data and relates to the period between 31 December 2017 and 31 December 2019. Simulated past performance does not represent actual performance and should not be used as a guide to actual or future performance. North American Marijuana Index: The calculation of this index began on 02 March 2017 and therefore it is not possible to show actual performance for any complete 12 month periods prior to 2018. Accordingly, the performance shown is actual past performance relating to the period between 31 December 2017 and 31 December 2019. Both indices: All performance and volatility data is in USD, unless otherwise stated. Volatility has been calculated as the two-year annualised standard deviation of the daily returns. The performance data shown does not reflect the transaction costs and management fees incurred or charged by financial products such as FLWR. Please note that the value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested. If your investment currency is different to USD, then the return you will get from your investment may increase or decrease as a result of currency fluctuations between USD and your investment currency.

18

19

Trading Information

ETF • • • • • • • • • Rize Medical Cannabis and Life Sciences UCITS ETF • • • • • • • • • • • • • • • • •

Base Currency • • • • • • • USD • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

Total Expense Ratio • • • • • 0.65% • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

Inception Date • • • • • • • Monday, 10 February 2020 • • • • • • • • • • • • • • • • • • • • • • • •

ISIN • • • • • • • • • IE00BJXRZ273 • • • • • • • • • • • • • • • • • • • • • • • • • • •

Base Code • • • • • • • • FLWR • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

Listings and Tickers • • • • • London Stock Exchange • • • • • • • • • • • • • • FLWR (USD), FLWG (GBP) • • •

• • • • • • • • • • • Deutsche Börse • • • • • • • • • • • • • • • • BLUM (EUR) • • • • • • •

Index / Ticker • • • • • • • Foxberry Medical Cannabis & Life Sciences Index / FXBYFLWR • • • • • • • • • • • • • • •

Thematic Industry Classification • • New Frontier Data® Sector Classifications • • • • • • • • • • • • • • • • • • • •

Index Replication Method • • • • Physical - Full Replication • • • • • • • • • • • • • • • • • • • • • • • •

Income Treatment • • • • • • Accumulating • • • • • • • • • • • • • • • • • • • • • • • • • • •

UCITS • • • • • • • • • Yes • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

Domicile • • • • • • • • Ireland • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

Fund Type • • • • • • • • Irish ICAV • • • • • • • • • • • • • • • • • • • • • • • • • • • •

Issuer • • • • • • • • • Rize UCITS ICAV • • • • • • • • • • • • • • • • • • • • • • • • • •

Promoter • • • • • • • • Rize ETF Limited • • • • • • • • • • • • • • • • • • • • • • • • • •

Investment Manager • • • • • Davy Global Fund Management Limited • • • • • • • • • • • • • • • • • • • • •

Manager • • • • • • • • Davy Global Fund Management Limited • • • • • • • • • • • • • • • • • • • • •

Depositary/Custodian • • • • • Northern Trust Fiduciary Services (Ireland) Limited • • • • • • • • • • • • • • • • • •

ISA Eligible (UK) • • • • • • Yes • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

SIPP Eligible (UK) • • • • • • Yes • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

UK Reporting Fund Status (UK) • • • Yes • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

Equity Fund (Germany) • • • • • Yes • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

Investment Fund Status (Germany) • • Yes • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

20

R I Z E I S E U R O P E ’ S F I R S T S P E C I A L I S T T H E M A T I C E T F I S S U E R

At Rize ETF, we believe there’s a better way to invest in the future. Our ETFs provide investors with unprecedented access to the megatrends that are transforming our world. We believe we’re pioneering a new way of investing, one that enables investors of all stripes to generate long-term returns whilst staying on the right side of history.

We are committed to challenging orthodoxy and providing investors with seamless access to the most ground-breaking megatrends shaping our planet.

21

Important Information

This document is issued by Rize ETF Limited. Rize ETF Limited is an Appointed Representative of Aldgate Advisors Limited, a firm authorised and regulated by the Financial Conduct Authority (FCA FRN 763187). Rize ETF Limited is registered in England and Wales number 11770079.

The information contained in this document is solely intended for professional investors as defined within the meaning of the Markets in Financial Instruments Directive (MiFID) (the “Directive”). Persons who do not fall within this definition should return this document immediately to Rize ETF Limited and should not review the remainder of the material, and in any event, must not act or rely upon the information contained in this document. By continuing to review this document, each person is deemed to confirm, warrant and represent that they fit within the definition of professional investor within the meaning of the Directive.

This document is not being provided to you on the basis that you are a client of Rize ETF Limited. Rize ETF Limited is not acting on your behalf and is not responsible for providing protections that would otherwise be afforded to clients of Rize ETF Limited.

This document is for information purposes only. Its contents, and the fact of its distribution, do not constitute investment advice, nor do they constitute tax, legal or any other form of advice. It does not constitute or form part of any offer to issue or sell, or the solicitation of any offer to buy or sell any investment. It shall not form the basis of, or be relied upon in connection with, any contract. Where this document contains past performance and projected performance information, it must be noted that past performance and projected performance is not a reliable indicator of future performance. Simulated past performance does not represent actual past performance and should not be used as a guide to actual past or future performance.

Capital at Risk Warning – Please note that the value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested. If your investment currency is different to the Funds’ currency of denomination (USD) or the currencies in which the Funds’ assets are denominated (which may be a range of different global currencies) , then the return you will get from your investment may increase or decrease as a result of currency fluctuations between your investment currency and such currencies.

The products referred to in this document are offered by Rize UCITS ICAV (the “ICAV”). The ICAV is an open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with variable capital and segregated liability between its sub-funds (each, a “Fund”) and registered in Ireland with registration number C193010 and authorised by the Central Bank of Ireland as a UCITS. The ICAV is managed by Davy Global Fund Management Limited.

The Funds are not offered or aimed at residents in any country in which (a) the ICAV and the Funds are not authorised or registered for distribution and where to do so is contrary to the relevant country’s securities laws, (b) the dissemination of information relating to the ICAV and the Funds via the internet is forbidden, and/or Rize ETF Limited is not authorised or qualified to make such offer or invitation.

The Funds may be registered or otherwise approved for distribution to the public in one or more European jurisdictions. Where this is the case, a country-specific web page and copies of the relevant prospectus, fund supplements, any country-specific supplements, KIIDs, constitutional documents and the latest annual and semi-annual reports relating to the ICAV and the latest Net Asset Values of the Funds (or any share classes thereof (each, a “Share Class”) (the “Fund Information”) will be available at http://www.rizeetf.com. The fact of such a registration or approval, however, does not mean that any regulator (including the FCA) has determined that the Funds (or any Share Classes thereof) are suitable for all categories of investors. Investors should continue to consider the terms of investment in any Fund (or Share Class thereof) carefully and seek professional investment advice before taking any decision to invest in such Fund (or Share Class thereof).

United Kingdom: For the purposes of the United Kingdom Financial Services and Markets Act 2000 (“FSMA”), the ICAV is a UCITS that has been recognised by the Financial Conduct Authority (the “FCA”). The Fund Information can be obtained free of charge upon request from the Facilities Agent in the United Kingdom, Davy Global Fund Management Limited, at Dashwood House, 69 Old Broad Street, London, EC2M 1QS.

Germany: The offering of the Shares of the ICAV has been notified to the German Financial Services Supervisory Authority (BaFin) in accordance with section 310 of the German Investment Code (KAGB). The Fund Information (including the KIIDs in German language) can be obtained free of charge upon request from the Information Agent in Germany, German Fund Information Service Ug (Haftungsbeschränkt), at Zum Eichhagen 4, 21382 Brietlingen, Germany.

United States: This document and its contents are not directed at any person that is resident in the United States (“US person”), and no offer or invitation is made to any US person to acquire or sell any service, product or security referred to. The provision of any information in this document does not constitute an offer to US persons to purchase securities.

Further information about the Funds (and Share Classes thereof) described in this document, such as details of the key underlying investments of the Funds and share prices, is available at http://www.rizeetf.com or from your broker or financial adviser. The indicative intra-day net asset values of the Share Classes of the Funds are available at http://www.solactive.com. A UCITS ETF’s units / shares that have been acquired on the secondary market cannot usually be sold directly back to the UCITS ETF itself. Investors who are not Authorised Participants must buy and sell shares on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees and additional taxes in doing so. In addition, as the market price at which the Shares are traded on the secondary market may differ from the Net Asset Value per Share, investors may pay more than the then current Net Asset Value per Share when buying shares and may receive less than the current Net Asset Value per Share when selling them. Any decision to invest must be based solely on the information contained in the relevant prospectus, fund supplements, any country-specific supplements, KIIDs, constitutional documents and the latest annual and semi-annual reports relating to the ICAV. Investors should read the Fund-specific risks in the ICAV’s prospectus and any Fund-specific supplement and KIID.

22

F U T U R EF I R S TE T F S

rizeetf.com

For more information, email us at info@rizeetf.com